The most likely diagnosis for this patient is androgen insensitivity syndrome (AIS). This is because she has not started menstruating by the age of 15, has little to no axillary or pubic hair, and elevated testosterone levels. These symptoms are all indicative of AIS, which is a genetic condition where individuals with male chromosomes (46XY) have a female appearance due to their body’s resistance to testosterone. The lower pelvic masses seen on examination are likely to be undescended testes.

Congenital adrenal hyperplasia (CAH) is an unlikely diagnosis as it typically causes excess male-pattern hair growth, including axillary and pubic hair, which is not seen in this patient. Additionally, CAH would not explain the presence of the lower pelvic masses.

Functional hypothalamic amenorrhoea is also unlikely as this condition is typically associated with low body weight, which is not the case for this patient. Furthermore, her FSH and LH levels are within the normal range, indicating that there is no hypothalamic dysfunction.

Polycystic ovarian syndrome (PCOS) is an unlikely diagnosis as it typically causes irregular periods rather than a complete absence of menstruation. Additionally, patients with PCOS often have excessive hair growth, which is not seen in this patient. PCOS would also not explain the presence of the lower pelvic masses.

Understanding Androgen Insensitivity Syndrome

Androgen insensitivity syndrome is a genetic condition that affects individuals with an XY genotype, causing them to develop a female phenotype due to their body’s resistance to testosterone. This condition was previously known as testicular feminization syndrome. The main features of this condition include primary amenorrhea, little or no pubic and axillary hair, undescended testes leading to groin swellings, and breast development due to the conversion of testosterone to estrogen.

Diagnosis of androgen insensitivity syndrome can be made through a buccal smear or chromosomal analysis, which reveals a 46XY genotype. After puberty, testosterone levels in affected individuals are typically in the high-normal to slightly elevated range for postpubertal boys.

Management of androgen insensitivity syndrome involves counseling and raising the child as female. Bilateral orchidectomy is recommended to reduce the risk of testicular cancer due to undescended testes. Additionally, estrogen therapy may be used to promote the development of secondary sexual characteristics.

In summary, androgen insensitivity syndrome is a genetic condition that affects the development of individuals with an XY genotype, causing them to develop a female phenotype. Early diagnosis and management can help affected individuals lead healthy and fulfilling lives.

Premature Ovarian Insufficiency: Causes and Management

Premature ovarian insufficiency is a condition where menopausal symptoms and elevated gonadotrophin levels occur before the age of 40. It affects approximately 1 in 100 women and can be caused by various factors such as idiopathic reasons, family history, bilateral oophorectomy, radiotherapy, chemotherapy, infection, autoimmune disorders, and resistant ovary syndrome. The symptoms of premature ovarian insufficiency are similar to those of normal menopause, including hot flushes, night sweats, infertility, secondary amenorrhoea, raised FSH and LH levels, and low oestradiol.

Management of premature ovarian insufficiency involves hormone replacement therapy (HRT) or a combined oral contraceptive pill until the age of the average menopause, which is 51 years. It is important to note that HRT does not provide contraception in case spontaneous ovarian activity resumes. Early diagnosis and management of premature ovarian insufficiency can help alleviate symptoms and improve quality of life for affected women.

Breast Masses: Differential Diagnosis and Clinical Features

Breast masses are a common concern for women, and it is important to differentiate between benign and malignant causes. Here, we discuss the clinical features and differential diagnosis of various breast masses.

Diffuse cystic mastopathy is a benign condition that affects a significant proportion of women. It is characterized by the formation of cysts in the breast lobules due to hormonal changes in the menstrual cycle. The lumps are smooth, mobile, and tend to peak in size before each period. Diagnosis is primarily based on clinical examination, but a biopsy may be needed to confirm the diagnosis.

Fat necrosis is another benign condition that can occur due to direct trauma or surgery. It is characterized by the formation of firm, round, and painless masses in the breast. The skin around the lump may be red or bruised, and a biopsy may be needed to differentiate it from breast cancer.

Breast abscesses are characterized by local inflammation, pain, and fever. They may be associated with previous breast infections and may require drainage. However, there is no evidence of an infectious process in this patient.

Breast cancer is a concern in any patient with a breast mass, but early breast cancer is often asymptomatic. Physical findings that may indicate the possible presence of breast cancer include changes in breast size or shape, skin dimpling or changes, nipple abnormalities, and axillary lumps. However, none of these symptoms are present in this patient.

Fibroadenoma is the most common cause of breast mass in women under 35 years of age. It is characterized by a singular, firm, rubbery, smooth, and mobile mass. However, this patient reports multiple lumps, making a diagnosis of fibroadenoma less likely.

In conclusion, the cyclic nature of this patient’s breast masses makes diffuse cystic mastopathy the most likely diagnosis. However, a biopsy may be needed to confirm the diagnosis and rule out other causes.

During pregnancy, women with epilepsy should take 5mg of folic acid. Additionally, due to the potential harm of antiepileptic drugs to the fetus, they should receive specialized medical care.

Pregnancy and breastfeeding can be a concern for women with epilepsy. It is generally recommended that women continue taking their medication during pregnancy, as the risks of uncontrolled seizures outweigh the potential risks to the fetus. However, it is important for women to take folic acid before pregnancy to reduce the risk of neural tube defects. The use of antiepileptic medication during pregnancy can increase the risk of congenital defects, but this risk is still relatively low. It is recommended to aim for monotherapy and there is no need to monitor drug levels. Sodium valproate is associated with neural tube defects, while carbamazepine is considered the least teratogenic of the older antiepileptics. Phenytoin is associated with cleft palate, and lamotrigine may require a dose increase during pregnancy. Breastfeeding is generally safe for mothers taking antiepileptics, except for barbiturates. Pregnant women taking phenytoin should be given vitamin K in the last month of pregnancy to prevent clotting disorders in the newborn.

A warning has been issued about the use of sodium valproate during pregnancy and in women of childbearing age. New evidence suggests a significant risk of neurodevelopmental delay in children following maternal use of this medication. Therefore, it should only be used if clearly necessary and under specialist neurological or psychiatric advice. It is important for women with epilepsy to discuss their options with their healthcare provider and make informed decisions about their treatment during pregnancy and breastfeeding.

If the COC is not started on the first day of the next period, it is important to follow the standard guidelines and use condoms for 7 days.

Special Situations for Combined Oral Contraceptive Pill

Concurrent antibiotic use has been a concern for many years in the UK, as doctors have advised that it may interfere with the effectiveness of the combined oral contraceptive pill. However, this approach is not taken in the US or most of mainland Europe. In 2011, the Faculty of Sexual & Reproductive Healthcare updated their guidelines to abandon the extra precautions previously advised during antibiotic treatment and for 7 days afterwards. The latest edition of the British National Formulary (BNF) has also been updated to reflect this guidance, although precautions should still be taken with enzyme-inducing antibiotics such as rifampicin.

When it comes to switching combined oral contraceptive pills, the BNF and Faculty of Sexual & Reproductive Healthcare (FSRH) appear to give contradictory advice. The FSRH’s Combined Oral Contraception guidelines state that the pill-free interval does not need to be omitted, while the BNF advises missing the pill-free interval if the progesterone changes. Given this uncertainty, it is best to follow the BNF’s advice.

The use of combined oral contraceptive pills is completely contraindicated in patients with migraine with aura due to an increased risk of ischaemic stroke (UKMEC class 4). However, progestogen-based contraception methods and the levonorgestrel-releasing intrauterine device are considered safe (UKMEC 2) as the benefits of using these methods outweigh the potential risks. The copper intrauterine device is the only form of contraception recommended by UKMEC as having no contraindication in this condition (UKMEC 1).

Intrauterine contraceptive devices include copper IUDs and levonorgestrel-releasing IUS. Both are over 99% effective. The IUD prevents fertilization by decreasing sperm motility, while the IUS prevents endometrial proliferation and thickens cervical mucus. Potential problems include heavier periods with IUDs and initial bleeding with the IUS. There is a small risk of uterine perforation, ectopic pregnancy, and infection. New IUS systems, such as Jaydess® and Kyleena®, have smaller frames and less levonorgestrel, resulting in lower serum levels and different rates of amenorrhea.

The most significant risk factor for cervical cancer is infection with the human papillomavirus (HPV), particularly types 16, 18, and 33. Among the approximately 15 types of HPV that are considered high-risk for cervical cancer, HPV 16 and 18 are responsible for about 70% of cases. HPV 6 and 11, on the other hand, are associated with the formation of genital warts.

Understanding Cervical Cancer: Risk Factors and Mechanism of HPV

Cervical cancer is a type of cancer that affects the cervix, which is the lower part of the uterus. It is most commonly diagnosed in women under the age of 45, with the highest incidence rates occurring in those aged 25-29. The cancer can be divided into two types: squamous cell cancer and adenocarcinoma. Symptoms may include abnormal vaginal bleeding, postcoital bleeding, intermenstrual bleeding, or postmenopausal bleeding, as well as vaginal discharge.

The most important factor in the development of cervical cancer is the human papillomavirus (HPV), particularly serotypes 16, 18, and 33. Other risk factors include smoking, human immunodeficiency virus, early first intercourse, many sexual partners, high parity, and lower socioeconomic status. While the association between combined oral contraceptive pill use and cervical cancer is sometimes debated, a large study published in the Lancet confirmed the link.

The mechanism by which HPV causes cervical cancer involves the production of oncogenes E6 and E7 by HPV 16 and 18, respectively. E6 inhibits the p53 tumour suppressor gene, while E7 inhibits the RB suppressor gene. Understanding the risk factors and mechanism of HPV in the development of cervical cancer is crucial for prevention and early detection. Regular cervical cancer screening is recommended for all women.

The cessation of oestradiol and progesterone production in the ovaries, which can be caused naturally or by medical intervention, leads to menopause. This decrease in hormone production often results in elevated levels of FSH and LH.

Understanding Menopause and Contraception

Menopause is a natural biological process that marks the end of a woman’s reproductive years. On average, women in the UK experience menopause at the age of 51. However, prior to menopause, women may experience a period known as the climacteric. During this time, ovarian function starts to decline, and women may experience symptoms such as hot flashes, mood swings, and vaginal dryness.

It is important for women to understand that they can still become pregnant during the climacteric period. Therefore, it is recommended to use effective contraception until a certain period of time has passed. Women over the age of 50 should use contraception for 12 months after their last period, while women under the age of 50 should use contraception for 24 months after their last period. By understanding menopause and the importance of contraception during the climacteric period, women can make informed decisions about their reproductive health.

The patient is suffering from thrush and requires antifungal medication. However, since the patient is pregnant, oral fluconazole cannot be prescribed due to its link with birth defects. Instead, metronidazole can be used to treat bacterial vaginosis and Trichomonas vaginalis.

Vaginal candidiasis, also known as thrush, is a common condition that many women can diagnose and treat themselves. Candida albicans is responsible for about 80% of cases, while other candida species cause the remaining 20%. Although most women have no predisposing factors, certain factors such as diabetes mellitus, antibiotics, steroids, pregnancy, and HIV can increase the likelihood of developing vaginal candidiasis. Symptoms include non-offensive discharge resembling cottage cheese, vulvitis, itching, vulval erythema, fissuring, and satellite lesions. A high vaginal swab is not routinely indicated if the clinical features are consistent with candidiasis. Treatment options include local or oral therapy, with oral fluconazole 150 mg as a single dose being the first-line treatment according to NICE Clinical Knowledge Summaries. If there are vulval symptoms, a topical imidazole may be added to an oral or intravaginal antifungal. Pregnant women should only use local treatments. Recurrent vaginal candidiasis is defined as four or more episodes per year by BASHH. Compliance with previous treatment should be checked, and a high vaginal swab for microscopy and culture should be performed to confirm the diagnosis. A blood glucose test may be necessary to exclude diabetes, and differential diagnoses such as lichen sclerosus should be ruled out. An induction-maintenance regime involving oral fluconazole may be considered. Induction involves taking oral fluconazole every three days for three doses, while maintenance involves taking oral fluconazole weekly for six months.

To ensure the effectiveness of the contraceptive patch, it should be applied to clean, dry skin on a weekly basis for three weeks, followed by a patch-free week to stimulate a withdrawal bleed. However, if the patch change is delayed for more than 48 hours, it is important to change it immediately and use a barrier method of contraception for the next 7 days. In case of unprotected intercourse, emergency contraceptives should be considered.

The Evra patch is the only contraceptive patch that is approved for use in the UK. The patch cycle lasts for four weeks, during which the patch is worn every day for the first three weeks and changed weekly. During the fourth week, the patch is not worn, and a withdrawal bleed occurs.

If a woman delays changing the patch at the end of week one or two, she should change it immediately. If the delay is less than 48 hours, no further precautions are necessary. However, if the delay is more than 48 hours, she should change the patch immediately and use a barrier method of contraception for the next seven days. If she has had unprotected sex during this extended patch-free interval or in the last five days, emergency contraception should be considered.

If the patch removal is delayed at the end of week three, the woman should remove the patch as soon as possible and apply a new patch on the usual cycle start day for the next cycle, even if withdrawal bleeding is occurring. No additional contraception is needed.

If patch application is delayed at the end of a patch-free week, additional barrier contraception should be used for seven days following any delay at the start of a new patch cycle. For more information, please refer to the NICE Clinical Knowledge Summary on combined hormonal methods of contraception.